CN114891832B - Construction method and application of recombinant lentivirus for over-expressing bovine TUSC5a and TUSC5b genes - Google Patents
Construction method and application of recombinant lentivirus for over-expressing bovine TUSC5a and TUSC5b genes Download PDFInfo
- Publication number
- CN114891832B CN114891832B CN202210587879.9A CN202210587879A CN114891832B CN 114891832 B CN114891832 B CN 114891832B CN 202210587879 A CN202210587879 A CN 202210587879A CN 114891832 B CN114891832 B CN 114891832B
- Authority
- CN
- China
- Prior art keywords
- tusc5a
- tusc5b
- sequence
- bovine
- over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 73
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 54
- 241000713666 Lentivirus Species 0.000 title claims abstract description 51
- 238000010276 construction Methods 0.000 title claims abstract description 14
- 230000008021 deposition Effects 0.000 claims abstract description 37
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 235000015278 beef Nutrition 0.000 claims abstract description 23
- 239000013598 vector Substances 0.000 claims abstract description 21
- 241000700605 Viruses Species 0.000 claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 claims abstract description 18
- 238000004806 packaging method and process Methods 0.000 claims abstract description 17
- 238000009825 accumulation Methods 0.000 claims abstract description 12
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 12
- 102000003960 Ligases Human genes 0.000 claims abstract description 8
- 108090000364 Ligases Proteins 0.000 claims abstract description 8
- 238000011084 recovery Methods 0.000 claims abstract description 7
- 238000010367 cloning Methods 0.000 claims abstract description 5
- 108010042407 Endonucleases Proteins 0.000 claims abstract description 4
- 102000004533 Endonucleases Human genes 0.000 claims abstract description 3
- 239000003292 glue Substances 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 230000035508 accumulation Effects 0.000 claims description 9
- 238000001976 enzyme digestion Methods 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 101100520452 Arabidopsis thaliana PMD2 gene Proteins 0.000 claims description 5
- KEYDJKSQFDUAGF-YIRKRNQHSA-N prostaglandin D2 ethanolamide Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(=O)NCCO)[C@@H](O)CC1=O KEYDJKSQFDUAGF-YIRKRNQHSA-N 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 230000001276 controlling effect Effects 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 abstract description 21
- 101000788363 Homo sapiens Trafficking regulator of GLUT4 1 Proteins 0.000 abstract description 11
- 102100025212 Trafficking regulator of GLUT4 1 Human genes 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000001502 gel electrophoresis Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 4
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 4
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 4
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 4
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 4
- 102000000536 PPAR gamma Human genes 0.000 description 4
- 108010016731 PPAR gamma Proteins 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 101150097713 SCD1 gene Proteins 0.000 description 4
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application discloses a construction method and application of an over-expression bovine TUSC5a and TUSC5b gene recombinant slow virus, wherein the over-expression recombinant slow virus can regulate and control fat deposition as an invasive tool or as an artificial agent, the expression of TUSC5a can obviously promote fat synthesis and accumulation, and the expression of TUSC5b can obviously inhibit fat synthesis and accumulation. The construction method comprises (1) cloning TUSC5a and TUSC5b sequences; (2) Double-enzyme cutting TUSC5a and TUSC5b sequences carrying HIS labels with slow virus vectors respectively by using endonuclease, and connecting the products after glue recovery by using ligase to obtain the over-expression recombinant slow virus; (3) a step of verifying the over-expression recombinant lentivirus; (4) a step of packaging the over-expressed recombinant lentivirus. The application can correctly recognize the regulation network of TUSC5 on fat deposition to reach the level of splicing isomers, and the two packaged TUSC5 splicing isomer slow viruses can be used as a tool for manually regulating the fat deposition capacity of beef cattle, thereby realizing the dosage regulation of the fat deposition capacity.
Description
Technical Field
The application relates to the technical field of genetic engineering, in particular to a construction method and application of a recombinant lentivirus for overexpressing bovine TUSC5a and TUSC5b genes.
Background
Fat deposition ability is an important factor in determining the economic value of beef cattle. The selling prices of the beef fat tissues at different positions are greatly different. Subcutaneous and intraperitoneal fat deposition (tallow) costs around 6 yuan/kg; if fat is deposited in the muscle, snowflake beef can be formed, the beef quality is obviously improved, and the price is about 1500 yuan/kg. Therefore, the ability to control fat deposition at different locations is now a key to scientific research and to increase the economic value production of beef cattle. TUSC5 has been shown to be an important gene regulating fat deposition in humans, mice and cattle. The gene is worth noting that the gene is specifically and highly expressed in adipose tissues, the characteristic can ensure that the gene can not influence the growth and development of other tissues under the premise of manual regulation, and the tissue-specific start expression is not needed to be considered when preparing a relevant bioengineering regulation tool, so that the operation is simpler and more convenient. The above demonstrates that TUSC5 has great potential in achieving artificial regulation of fat deposition.
It was found that there are two different alternative splice isomers of TUSC5, TUSC5a and TUSC5b, but it is not clear at present whether both have a regulatory effect on fat deposition, and whether the extent of the regulatory effect of both on fat deposition is consistent. Previous studies demonstrated that alternative splicing would result in different transcripts produced from the same gene would have different and even opposite functions. Therefore, resolving the regulatory effect of two different splice isomers of TUSC5 on fat deposition is essential for its use in artificial regulation of bovine fat deposition.
The slow virus can integrate the genome sequence of the slow virus into a host cell by infecting cells or tissues, thereby realizing the effect of continuous expression of a target gene in target tissues, further regulating the development of the cells or tissues, realizing the purpose of artificial regulation, and being an effective genetic engineering means, and having wider application at present. By constructing and packaging lentiviruses that overexpress TUSC5a and TUSC5b, on the one hand, the regulatory capacity of both on fat deposition can be studied in adipocyte cell lines; on the other hand, on the basis of defining the regulation of fat deposition ability by two different splice isomers, a potential effective tool with the capacity of manually regulating fat deposition can be developed.
Therefore, the research builds and packages the TUSC5a and TUSC5b lentivirus by searching proper conditions, analyzes the difference of the capacity of the TUSC5a and TUSC5b on fat deposition on the basis, lays a foundation for further developing an effective biological tool for manually regulating and controlling the fat deposition capacity of beef cattle in the future, and provides necessary materials for rapidly improving the economic value of beef cattle.
Disclosure of Invention
The first object of the present application is to provide the use of the bovine TUSC5a and TUSC5b genes in the regulation of fat deposition in beef cattle, the TUSC5a and TUSC5b genes being two splice isomers of the bovine TUSC5 gene.
The second object of the present application is to provide the use of recombinant lentiviruses overexpressing the bovine TUSC5a and TUSC5b genes, which are two splice isomers of the bovine TUSC5 gene, in the regulation of fat deposition in beef cattle.
A third object of the present application is to provide an artificial formulation for regulating fat deposition in beef cattle.
The fourth object of the present application is to provide a method for constructing recombinant lentiviruses over-expressing bovine TUSC5a/TUSC5b genes, the TUSC5a and TUSC5b genes being two splice isomers of the bovine TUSC5 gene.
In order to achieve the above purpose, the application adopts the following technical scheme:
the application of the bovine TUSC5a and TUSC5b genes in the regulation and control of fat deposition of beef cattle, the expression of TUSC5a obviously promotes the synthesis and accumulation of fat, the expression of TUSC5b obviously inhibits the synthesis and accumulation of fat, the TUSC5a sequence is shown as SEQ ID No.1, and the TUSC5b sequence is shown as SEQ ID No. 2. Specifically, a molecular tool for editing TUSC5a and TUSC5b genes can be constructed into a virus for targeting infected bovine cells, and the target can enter a bovine body through intravenous injection or oral administration and the like to be integrated into a bovine genome for expression, so that the purposes of regulating and controlling fat deposition capacity and regulating and controlling beef quality are achieved.
The application of the recombinant slow virus of the over-expressed bovine TUSC5a and TUSC5b genes in beef cattle fat deposition regulation, the slow virus integrates the TUSC5a and TUSC5b genes into a genome to express and regulate fat deposition, the expression of the TUSC5a obviously promotes fat synthesis and accumulation, the expression of the TUSC5b obviously inhibits fat synthesis and accumulation, the TUSC5a sequence is shown as SEQ ID No.1, and the TUSC5b sequence is shown as SEQ ID No. 2. Specifically, the recombinant lentiviruses of the overexpression bovine TUSC5a and TUSC5b genes can be taken as a molecular tool to enter the bovine body for integration into the bovine genome for expression by intravenous injection, oral administration or the like.
An artificial preparation for regulating fat deposition in beef cattle, comprising an over-expression slow virus vector for over-expressing bovine TUSC5a/TUSC5b genes. The artificial preparation has the potential for manually regulating fat deposition capacity or parts, further regulating beef quality, and can be used for manually regulating beef fat deposition and production of high-grade beef.
The construction method of the over-expression bovine TUSC5a/TUSC5b gene recombinant lentivirus comprises the steps of respectively carrying out double enzyme digestion on TUSC5a/TUSC5b sequences carrying HIS labels and lentivirus vectors by using endonuclease, and connecting the products after glue recovery by using ligase to obtain the over-expression bovine TUSC5a/TUSC5b gene recombinant lentivirus;
the lentiviral vector is pCDH-CMV-MCS-EF 1-copGGFP-T2A-Puro, and the sequence added to the lentiviral vector connected by the ligase is as follows:
5'-ccg (protecting base) +GAATTC (ECOR 1) +ATG+TUSC5a/TUSC5b sequence + CATCATCACCATCACCAT (HIS tag sequence) +CCTAGG (BAMH 1) +cgc (protecting base) -3',
the TUSC5a sequence is shown as SEQ ID No.1, the TUSC5b sequence is shown as SEQ ID No.2, the sequence added on the lentiviral vector after the TUSC5a sequence is connected is shown as SEQ ID No.3, and the sequence added on the lentiviral vector after the TUSC5b sequence is connected is shown as SEQ ID No. 4.
Still further, the method further comprises the step of cloning TUSC5a/TUSC5b sequence, specifically:
cDNA obtained from bovine adipose tissue, a first fragment of TUSC5a was amplified using TUSC5a-F and TUSC5a-overlap-R as primers, and a second fragment of TUSC5a was amplified using TUSC5a-overlap-F and TUSC5a-RED1-R2 as primers; after the PCR product gel is recovered, TUSC5a-F, TUSC5a-RED1-R2 is used as a template, and is used as a primer for amplification to obtain a TUSC5a sequence; TUSC5a-F, TUSC a-RED1-R1 is used as a primer to amplify to obtain a TUSC5b sequence, after HindI and KpnI are subjected to double enzyme digestion, gel recovery products are subjected to T4 ligase to construct TUSC5a-RED1 and TUSC5b-RED1;
wherein, the sequences of the primers are shown in the following table:
still further, the method further comprises the step of adding an HIS tag to the TUSC5a/TUSC5b sequence, specifically:
using TUSC5a-RED1 as template, using primer TUSC5a-F, TUSC5a-R to amplify TUSC5a sequence carrying HIS tag;
using TUSC5b-RED1 as template, using primer TUSC5b-F, TUSC5b-R to amplify TUSC5b sequence carrying HIS tag;
wherein, the sequences of the primers are shown in the following table:
the PCR amplification system (20. Mu.L) of TUSC5a-RED1 was as follows:
the PCR amplification system (20. Mu.L) of TUSC5b-RED1 was as follows:
further, the method comprises the step of integrating the recombinant lentivirus of the over-expressed bovine TUSC5a/TUSC5b gene into a host chromosome to construct a TUSC5a/TUSC5b stable transgenic cell line.
Still further, the method also comprises the step of packaging the recombinant lentivirus of the over-expressed bovine TUSC5a/TUSC5b gene, wherein the packaging system of the recombinant lentivirus of the over-expressed bovine TUSC5a/TUSC5b gene and the three plasmids Pspax2 and PMD2.G is used for packaging the lentivirus by using 293T cells as packaging cells.
Still further, pspax2: pmd2.G: the volume ratio of the recombinant lentivirus of the over-expressed bovine TUSC5a/TUSC5b gene is 2:3: 4.
The application has the beneficial effects that: according to the application, the pCDH-CMV-MCS-EF 1-copGGFP-T2A-Puro (LV 34) lentivirus is taken as a vector to construct two over-expression recombinant lentiviruses of TUSC5a and TUSC5b, the two over-expression recombinant lentiviruses are taken as a tool with infectivity or as an artificial preparation to regulate and control fat deposition, the expression of TUSC5a obviously promotes fat synthesis and accumulation, and the expression of TUSC5b obviously inhibits fat synthesis and accumulation. The application has the advantages that the regulation network of TUSC5 on fat deposition is correctly known to go deep into the level of splicing isomers, and the reverse regulation effect of TUSC5a and TUSC5b on fat deposition is found, and the two packaged TUSC5 splicing isomer slow viruses can be used as tools for manually regulating the fat deposition capacity of beef cattle, so that the dosage regulation of the fat deposition capacity is realized, and the application has important significance for quickly and manually promoting the economic value improvement of beef cattle in China.
Drawings
FIG. 1 is a graph showing the results of TUSC5a and TUSC5b gel electrophoresis;
FIG. 2 is a schematic diagram of construction of a recombinant lentivirus over-expressing the bovine TUSC5a, TUSC5b gene;
FIG. 3 is a graph showing the results of TUSC5a and TUSC5b vector enzyme-resolved gel electrophoresis;
FIG. 4 is a TUSC5a, TUSC5b vector sequencing verification result;
FIG. 5 is a fluorescent image of TUSC5a, TUSC5b lentiviral infected 293T cells;
FIG. 6 is a graph showing the results of the expression verification of TUSC5a, TUSC5b lentiviral infection 293T;
FIG. 7 is a graph showing the results of C3H10T1/2 induced differentiation of the TUSC5a and TUSC5b groups;
FIG. 8 is a graph of results of C3H10T1/2 induced differentiation oil red O staining over-expressing TUSC5a, TUSC5b groups;
FIG. 9 is a graph showing changes in gene expression during induced differentiation of C3H10T1/2 cells overexpressing TUSC5a, TUSC5b groups.
Detailed Description
The following examples are provided to further illustrate the application but are not to be construed as limiting the application and any modifications and alterations made thereto are within the scope of the application without departing from the spirit and scope thereof.
Unless otherwise stated, the technical means involved in the following examples are conventional techniques commonly used by those skilled in the art of graminess.
1. Construction of vectors
1. Cloning of TUSC5a and TUSC5b sequences
cDNA obtained from bovine adipose tissue, a first fragment of TUSC5a was amplified using TUSC5a-F and TUSC5a-overlap-R as primers, and a second fragment of TUSC5a was amplified using TUSC5a-overlap-F and TUSC5a-RED1-R2 as primers; after the PCR product gel is recovered, TUSC5a-F, TUSC5a-RED1-R2 is used as a template, and is used as a primer for amplification to obtain a TUSC5a sequence; TUSC5b sequence was obtained by amplification using TUSC5a-F, TUSC5a-RED1-R1 as a primer, and the size was verified by gel electrophoresis. The results of TUSC5a and TUSC5b gel electrophoresis are shown in FIG. 1. The amplified product gel electrophoresis results showed consistent band sizes for the TUSC5a and TUSC5b sequences. The TUSC5a sequence is shown as SEQ ID No.1, and the TUSC5b sequence is shown as SEQ ID No. 1. The sequences of the primers are shown in Table 1 below.
TABLE 1 TUSC5a and TUSC5b sequence cloning procedure each primer sequence
Overlapping amplification first step strategy (35 cycles):
overlapping amplification second step (35 cycles):
after double cleavage by Hind I and KpnI, the gel recovery products were stored by T4 ligase to construct TUSC5a-RED1 and TUSC5b-RED 1.
2. Construction of recombinant lentiviruses overexpressing TUSC5a, TUSC5b
The primer TUSC5a-F, TUSC5a-R was used to amplify the TUSC5a sequence carrying the HIS tag using TUSC5a-RED1 as template. TUSC5b sequence carrying the HIS tag was amplified using the primer TUSC5b-F, TUSC5b-R using TUSC5b-RED1 as a template.
Primer sequences to which HIS tags are added to the TUSC5a and TUSC5b sequences are shown in table 2. The PCR amplification system (20. Mu.L) of TUSC5a-RED1 is shown in Table 3. The PCR amplification system (20. Mu.L) of TUSC5b-RED1 is shown in Table 4.
TABLE 2 primer sequences to which HIS tags are added to TUSC5a and TUSC5b sequences
TABLE 3 PCR amplification System of TUSC5a-RED1 (20. Mu.L)
Amplification strategy:
TABLE 4 PCR amplification System of TUSC5b-RED1 (20. Mu.L)
Amplification strategy:
the TUSC5a and TUSC5b sequences carrying the HIS tag are respectively digested with pCDH-CMV-MCS-EF 1-copGGFP-T2A-pur (LV 34) lentiviral vector by ECOR1 and BAMH1 endonucleases, and the products after gel recovery are respectively connected by T4 DNA ligase to obtain the recombinant lentivirus of the overexpressed bovine TUSC5a and TUSC5b genes. FIG. 2 is a schematic diagram showing construction of a recombinant lentivirus over-expressing the bovine TUSC5a, TUSC5b gene.
Wherein T4 DNA ligase was used, incubated at 37℃for 2h and the ligation system (20. Mu.L) was as shown in Table 5.
TABLE 5 ligation System Using T4 DNA ligase (20. Mu.L)
Sequence addition to lentiviral vector cases: 5'-ccg (protecting base) +GAATTC (ECOR 1) +ATG+TUSC5a/TUSC5b sequence + CATCATCACCATCACCAT (his sequence) +CCTAGG (BAMH 1) +cgc (protecting base) -3'. The sequence added by the recombinant TUSC5a on the slow virus vector is shown as SEQ ID No.3, and the sequence added by the recombinant TUSC5b on the slow virus vector is shown as SEQ ID No. 4.
3. Verification of recombinant lentivirus overexpressing TUSC5a, TUSC5b
By utilizing the infection integration characteristic of the slow virus, the recombinant slow viruses of the over-expressed bovine TUSC5a and TUSC5b genes are respectively integrated on a host chromosome to achieve persistent expression, and TUSC5a and TUSC5b stable transgenic cell strains are constructed and used for cell function research of genes.
The method comprises the following specific steps:
(1) Taking 50 mu L of competent cells, adding 1 mu L of a connecting product (overexpressing bovine TUSC5a and TUSC5b gene recombination slow virus), gently mixing, and carrying out ice bath for 30min;
(2) Transferring to 42 ℃ for 90s, rapidly taking out and putting on ice for 2min, wherein the centrifuge tube cannot be shaken in the process;
(3) Adding 500 mu L of LB liquid medium without antibiotics, uniformly mixing, placing at 37 ℃ for 200r/min, and vibrating and culturing for 1h to revive bacteria;
(4) Taking 20 mu L of the mixture after gentle mixing, uniformly coating the mixture on LB solid medium containing ampicillin by using a coater, placing the flat plate in a constant temperature incubator at 37 ℃, inverting the flat plate after 30min, and continuously culturing for 12-14 h;
(5) On an ultra-clean workbench, single colonies are selected and inoculated into 3mL of LB liquid medium containing 100 mug/mL ampicillin, and the shaking culture is carried out for 10 hours at 37 ℃ at 220 r/min;
(6) Inoculating the culture on an ultra-clean workbench according to the proportion of 1/1000, and culturing in 200mL LB liquid medium containing 100 mug/mL ampicillin at 37 ℃ for 220r/min under shaking overnight;
(7) Centrifuging and collecting thalli at 8000r/min at 4 ℃ to extract the over-expression recombinant lentivirus;
(8) After the over-expression recombinant lentivirus is extracted, double enzyme digestion verification sequences are carried out, and each tube of reaction system is as follows:
and (3) carrying out enzyme digestion at 37 ℃, carrying out gel electrophoresis to obtain products, finding out areas corresponding to the sizes of the bands obtained by enzyme digestion and the target bands, and determining positive clones, wherein the gel electrophoresis result diagram of enzyme digestion of TUSC5a and TUSC5b vectors is shown in figure 3, and the gel electrophoresis result shows that TUSC5a and TUSC5b sequences are detected in enzyme digestion products, and the over-expression recombinant lentivirus is successfully constructed.
To further verify the construction of the recombinant lentiviruses of the overexpressed bovine TUSC5a and TUSC5b genes, the extracted recombinant lentiviruses were sequenced, and the sequence results were compared with the sequences of TUSC5a and TUSC5b, as shown in FIG. 4, which shows the results of the sequencing verification of the recombinant lentiviruses of the overexpressed bovine TUSC5a and TUSC5b genes, and the results show that the sequences of the recombinant lentiviruses are consistent with the sequences of TUSC5a and TUSC5b, and the construction of the recombinant lentiviruses of the overexpression is completed.
(9) And (3) culturing the over-expression recombinant slow virus again in a large quantity by using the corresponding positive bacterial liquid, and then extracting to obtain the over-expression recombinant slow virus for later use.
2. Packaging of recombinant lentiviruses over-expressing bovine TUSC5a, TUSC5b genes
1. Packaging of TUSC5a, TUSC5b overexpressed recombinant lentiviruses
The lentivirus is packaged by using 293T cells as packaging cells through a lentivirus core plasmid (namely over-expression recombinant lentivirus obtained by extracting a large amount of positive bacterial liquid in the steps), pspax2 and PMD2.G three-plasmid lentivirus packaging system. Because of the tag of the promoter COPGFP with independent CMV in the core plasmid, 293T cells expressed green fluorescent protein upon lentiviral packaging, which could be observed under a microscope.
293T cell inoculation: cells that had been passaged after resuscitation were used for culture and their growth was observed. Selecting cells in the logarithmic phase with normal morphology and no pollution. They were inoculated in six well plates (cell number of about 5X 105 cells per well) and placed in a 5% CO2 incubator at 37℃for culture.
Preparation of plasmids and transfection reagents: three plasmid DNA solutions, according to pmd2.G: psPAX2: the core plasmid is 2:3:4, and adding PBS to a constant volume of 200 mu L, and standing at room temperature for 30min.
Plasmid transfection: usingin vitro DNA transfection kit (Polyplus-transfer Co.) lentiviral expression systems were introduced into 293T cells, and specific steps were performed with reference to the instructions:
(1) Transfection is performed when 293T cells reach 70% -90% confluency;
(2) Fresh culture solution is replaced 1h to 2h before transfection, and 293T cell morphological changes are stimulated;
(3) Preparation of transfection complexes per well: 200 mu L jet PRIME Buffer is added to 3 sterile EP pipes of 1.5mL respectively, 9 mu g of pre-incubated lentiviral expression system mixed plasmid is added to each pipe respectively, the mixture is gently blown and mixed, 9 mu L of jet PRIME transfection reagent is added, and the mixture is gently blown and mixed to form a transfection complex;
(4) Incubating for 15min at room temperature;
(5) Adding the DNA-liposome complex into a cell culture solution, and shaking to make the cell culture solution uniform;
(6) Cells were cultured at 37℃for 8 hours, and the culture medium was changed.
(7) Collecting culture solution supernatants of 24h, 48h and 72h respectively, mixing, centrifuging the collected supernatant (4 ℃,4000, 10 min), and collecting the centrifuged supernatant; the supernatant was filtered on a super clean bench with a 0.45 μm filter screen.
As shown in FIG. 5, which shows fluorescence diagrams of TUSC5a, TUSC5b lentiviral infected 293T cells, the TUSC5a, TUSC5b, control groups were observed under a fluorescence microscope as apparent green fluorescence expression after 24h transfection of 293T cells with a lentiviral core plasmid, pspax2, PMD2.G three plasmid lentiviral packaging system.
2. Detection of recombinant lentiviruses over-expressing bovine TUSC5a and TUSC5b genes
After 293T cells were transfected with TUSC5a, TUSC5b, control lentiviral core plasmid, pspax2, PMD2.G three-plasmid lentiviral packaging system for 24h, cellular RNA and protein were extracted for detection, as shown in FIG. 6, which shows graphs of results of verification of expression of TUSC5a, TUSC5b lentiviral infection 293T cells, and the results showed that TUSC5a, TUSC5b, control group 293T cells were significantly improved on average at mRNA level and protein level after lentiviral infection.
RNA extraction:
(1) Removing the culture medium in the cell plate to be treated, gently washing the cells twice with PBS, sucking the waste liquid, adding 1mL of Trizol reagent into each hole, gently shaking the cell culture plate to ensure that the Trizol uniformly covers the cell surface, and incubating for 5min at room temperature;
(2) The cells were blown with RNase-free tips to complete lysis and the fluid was transferred to a 1.5mL EP tube;
(3) Adding 200 mu L of precooled chloroform into each tube, gently reversing for mixing for several times, and standing at room temperature for 10min;
(4) Labeling, sealing, centrifuging at 12000r/min at 4deg.C for 15min, standing at room temperature for 5min, and layering sample (upper water phase, middle layer is protein layer, lower phenol phase, and RNA is in upper water phase);
(5) Sucking the upper water phase (about 400 mu L) into a new 1.5mL EP tube, adding equal amount of pre-cooled isopropanol at-20deg.C, mixing thoroughly, and standing at room temperature for 10min;
(6) Labeling and sealing, and centrifuging at 12000r/min for 10min at 4 ℃ by using a centrifuge, wherein white RNA precipitation at the bottom of the tube can be seen (no obvious precipitation can be observed when the RNA amount is small);
(7) Removing supernatant, adding 1mL of 75% absolute cold ethanol into the precipitate, rinsing for 2 times (note that 75% absolute ethanol is prepared by DEPC water and is used at present), centrifuging for 5min at 8000r/min at 4deg.C, and drying excessive water in the tube by using clean cotton towel for the last time;
(8) Drying at room temperature for 5-10 min, making the precipitate semitransparent, adding appropriate amount of DEPC water, and dissolving in ice for 30min;
(9) 2 mu L of the concentration is measured by separate filling, 3 mu L of the gel is run to detect whether degradation exists, and the rest is stored at the temperature of minus 80 ℃ for standby.
Protein extraction:
(1) Preparing lysate (1 mL system): preparing 1000. Mu.L of high-strength RIPA lysate, adding 20. Mu.L of 50 XCocktail protease inhibitor, adding 10. Mu.L of phosphorylation protease inhibitor A, B solution and 10. Mu.L of PMSF reagent;
(2) Collecting a cell protein sample: the cells were washed 3 times with pre-chilled PBS and the residual solution was finally blotted thoroughly. 120-150. Mu.L of protein lysate was added to each well of cells, and the cell culture plate was placed on ice for 5min during which time the plate was repeatedly shaken to bring the lysate into full contact with the cells. Cells and lysates were collected in 1.5mL EP tubes with a clean cell scraper; the ice bath was repeated several times with 200. Mu.L of a pipette every 10min during 30min to ensure complete cell lysis. Centrifuging at 12000r/min for 5min at 4 ℃, and collecting the supernatant into a new EP tube to obtain the cellular protein.
3. Effect of overexpression of TUSC5a, TUSC5b on C3H10T1/2 induced differentiation
1. TUSC5a and TUSC5b overexpressing C3H10T1/2 cells induce differentiation
Maintenance was performed using reagent A (1.0. Mu. Mol/L rosiglitazone, 1.0. Mu. Mol/L dexamethasone, 10mg/L insulin, 0.5mmol/L IBMX) and 48h later with replacement of reagent B (1.0. Mu. Mol/L rosiglitazone, 10mg/L insulin). Lipogenesis was induced in TUSC5a, TUSC5B, control group C3H10T1/2 cells in an alternating fashion with reagent A and reagent B.
At 4d, the cells were stained with oil red O, as shown in FIG. 7, which shows the results of the induced differentiation of TUSC5a and TUSC5bC3H 10T1/2, as shown in FIG. 8, which shows the results of the induced differentiation of C3H10T1/2 of the groups TUSC5a and TUSC5b, which showed that the number and size of lipid droplets deposited in the TUSC5a group were higher than those in the TUSC5b and Control group was higher than those in the TUSC5b group, and it was found that the overexpression of TUSC5a increased the capacity of the induced differentiation of C3H10T1/2 compared with Control group, while the overexpression of TUSC5b group decreased the capacity of the induced differentiation of fat compared with Control group. In addition, apoptosis was found in C3H10T1/2 overexpressing TUSC5b when differentiation was induced for 4 d.
2. Gene expression changes during TUSC5a and TUSC5b overexpressing C3H10T1/2 cells induced differentiation
PPARgamma, FASN, FABP4 and SCD1 are important marker genes in fat deposition process, and we quantitatively detect and analyze the expression of the PPARgamma, FASN, FABP4 and SCD1 in the process of cell differentiation. As shown in FIG. 9, the results of the over-expression TUSC5A and TUSC5b C H10T1/2 induced differentiation oil red O staining are shown, the expression levels of PPARgamma, FASN, FABP4 and SCD1 are gradually increased within 0-6 days, the TUSC5A group is significantly higher than Control, and the TUSC5b group shows that the expression is significantly inhibited relative to Control. The expression level of PPARgamma, FASN, FABP4 and SCD1 was slowly decreased in 6-10 days. This reflects that expression of TUSC5a significantly promoted fat synthesis and accumulation, and expression of TUSC5B significantly inhibited fat synthesis and accumulation.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the application.
Sequence listing
<110> university of agriculture in China
<120> construction method of recombinant lentivirus of over-expressed bovine TUSC5a and TUSC5b genes and application thereof
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 618
<212> DNA
<213> cow (Bovine)
<400> 1
atggccaacc ccggacagcc tcagttttcc gcggcgcggg agccaggcac tgcctcaccc 60
ctgaacctgc cggagatgga gaagctcctt gtgcaggtcg ggggccagga tgacaagtcc 120
ctgaagccgt ccaagtccct ctcagggcct ctggacctgg agcagaatgg ccacagcctg 180
cccttcaagg tgatatccga ggagcaccgg gaagccttgc accccctctc atcctcccgg 240
gccagctcca ggagggcgtc ctccacggcc accacctcct atgcccagga cggagaagtt 300
cccaaagatt atctcatcct tgccatcgcc tcctgcttct gccccgtctg gcccctcaac 360
ctcatgcccc tcatcttttc catcatgtct cgaagtagcg tgcaacaggg ggacctggac 420
ggggcccgga ggctgggccg cctggccggg acgctcagca tcaccttcat catcatgggg 480
atcatcatca tcatcgtggc tgtgactgtc aactttgcag gaatcaaaac cccaaatcct 540
ccaaaaaggg accgggagac cctgtgttct gagctccgtc gtgctatcgc tgttcttttc 600
tttacagttc cgaagaaa 618
<210> 2
<211> 528
<212> DNA
<213> cow (Bovine)
<400> 2
gccaaccccg gacagcctca gttttccgcg gcgcgggagc caggcactgc ctcacccctg 60
aacctgccgg agatggagaa gctccttgtg caggtcgggg gccaggatga caagtccctg 120
aagccgtcca agtccctctc agggcctctg gacctggagc agaatggcca cagcctgccc 180
ttcaaggtga tatccgagga gcaccgggaa gccttgcacc ccctctcatc ctcccgggcc 240
agctccagga gggcgtcctc cacggccacc acctcctatg cccaggacgg agaagttccc 300
aaagattatc tcatccttgc catcgcctcc tgcttctgcc ccgtctggcc cctcaacctc 360
atgcccctca tcttttccat catgtctcga agtagcgtgc aacaggggga cctggacggg 420
gcccggaggc tgggccgcct ggccgggacg ctcagcatca ccttcatcat catggggatc 480
atcatcatca tcgtggctgt gactgtcaac tttgcagttc cgaagaaa 528
<210> 3
<211> 654
<212> DNA
<213> cow (Bovine)
<400> 3
ccggaattca tggccaaccc cggacagcct cagttttccg cggcgcggga gccaggcact 60
gcctcacccc tgaacctgcc ggagatggag aagctccttg tgcaggtcgg gggccaggat 120
gacaagtccc tgaagccgtc caagtccctc tcagggcctc tggacctgga gcagaatggc 180
cacagcctgc ccttcaaggt gatatccgag gagcaccggg aagccttgca ccccctctca 240
tcctcccggg ccagctccag gagggcgtcc tccacggcca ccacctccta tgcccaggac 300
ggagaagttc ccaaagatta tctcatcctt gccatcgcct cctgcttctg ccccgtctgg 360
cccctcaacc tcatgcccct catcttttcc atcatgtctc gaagtagcgt gcaacagggg 420
gacctggacg gggcccggag gctgggccgc ctggccggga cgctcagcat caccttcatc 480
atcatgggga tcatcatcat catcgtggct gtgactgtca actttgcagg aatcaaaacc 540
ccaaatcctc caaaaaggga ccgggagacc ctgtgttctg agctccgtcg tgctatcgct 600
gttcttttct ttacagttcc gaagaaacat catcaccatc accatcctag gcgc 654
<210> 4
<211> 567
<212> DNA
<213> cow (Bovine)
<400> 4
ccggaattca tggccaaccc cggacagcct cagttttccg cggcgcggga gccaggcact 60
gcctcacccc tgaacctgcc ggagatggag aagctccttg tgcaggtcgg gggccaggat 120
gacaagtccc tgaagccgtc caagtccctc tcagggcctc tggacctgga gcagaatggc 180
cacagcctgc ccttcaaggt gatatccgag gagcaccggg aagccttgca ccccctctca 240
tcctcccggg ccagctccag gagggcgtcc tccacggcca ccacctccta tgcccaggac 300
ggagaagttc ccaaagatta tctcatcctt gccatcgcct cctgcttctg ccccgtctgg 360
cccctcaacc tcatgcccct catcttttcc atcatgtctc gaagtagcgt gcaacagggg 420
gacctggacg gggcccggag gctgggccgc ctggccggga cgctcagcat caccttcatc 480
atcatgggga tcatcatcat catcgtggct gtgactgtca actttgcagt tccgaagaaa 540
catcatcacc atcaccatcc taggcgc 567
Claims (10)
1. The application of the bovine TUSC5a and TUSC5b genes in the regulation and control of fat deposition in beef cattle is characterized in that: the regulation is as follows: expression of TUSC5a significantly promotes fat synthesis and accumulation, expression of TUSC5b significantly inhibits fat synthesis and accumulation, TUSC5a sequence is shown in SEQ ID No.1, and TUSC5b sequence is shown in SEQ ID No. 2.
2. The use according to claim 1, characterized in that: the regulation of beef fat deposition by the bovine TUSC5a and TUSC5b genes is performed by overexpressing recombinant lentiviruses of the bovine TUSC5a and TUSC5b genes, which integrate TUSC5a and TUSC5b into the genomic gene expression and thereby regulate fat deposition.
3. The use according to claim 2, characterized in that: the recombinant slow virus of the over-expressed bovine TUSC5a/TUSC5b genes is used for preparing an artificial preparation for regulating and controlling fat deposition of beef cattle.
4. The use according to claim 2, characterized in that: the construction method of the recombinant lentivirus for over-expressing the bovine TUSC5a/TUSC5b genes comprises the following steps: the method comprises the steps of carrying out double enzyme digestion on TUSC5a/TUSC5b sequences carrying HIS labels and lentiviral vectors respectively by using endonucleases, and connecting products after glue recovery by using ligases to obtain the recombinant lentivirus of the overexpressed bovine TUSC5a/TUSC5b genes;
the lentiviral vector is pCDH-CMV-MCS-EF 1-copGGFP-T2A-Puro, and the sequence added to the lentiviral vector connected by the ligase is as follows:
5' -ccg +GAATTC+ATG+TUSC5a/TUSC5b sequence +
CATCATCACCATCACCAT+CCTAGG+cgc-3',
The TUSC5a sequence is shown as SEQ ID No.1, the TUSC5b sequence is shown as SEQ ID No.2, the sequence added on the lentiviral vector after the TUSC5a sequence is connected is shown as SEQ ID No.3, and the sequence added on the lentiviral vector after the TUSC5b sequence is connected is shown as SEQ ID No. 4.
5. The use according to claim 4, characterized in that: the method also comprises the step of cloning TUSC5a/TUSC5b sequence, specifically comprising the following steps:
cDNA obtained from bovine adipose tissue, a first fragment of TUSC5a was amplified using TUSC5a-F and TUSC5a-overlap-R as primers, and a second fragment of TUSC5a was amplified using TUSC5a-overlap-F and TUSC5a-RED1-R2 as primers; after the PCR product gel is recovered, TUSC5a-F, TUSC5a-RED1-R2 is used as a template, and is used as a primer for amplification to obtain a TUSC5a sequence; TUSC5a-F, TUSC a-RED1-R1 is used as a primer to amplify to obtain a TUSC5b sequence, after HindI and KpnI are subjected to double enzyme digestion, gel recovery products are subjected to T4 ligase to construct TUSC5a-RED1 and TUSC5b-RED1;
wherein, the sequences of the primers are shown in the following table:
6. the use according to claim 5, characterized in that: the method also comprises the step of adding an HIS tag to the TUSC5a/TUSC5b sequence, and specifically comprises the following steps:
using TUSC5a-RED1 as template, using primer TUSC5a-F, TUSC5a-R to amplify TUSC5a sequence carrying HIS tag;
using TUSC5b-RED1 as template, using primer TUSC5b-F, TUSC5b-R to amplify TUSC5b sequence carrying HIS tag;
wherein, the sequences of the primers are shown in the following table:
7. the use according to claim 6, characterized in that:
the PCR amplification system (20. Mu.L) of TUSC5a-RED1 was as follows:
the PCR amplification system (20. Mu.L) of TUSC5b-RED1 was as follows:
8. the use according to claim 4, characterized in that: the method also comprises the step of integrating the recombinant lentivirus of the over-expressed bovine TUSC5a/TUSC5b gene into a host chromosome to construct a TUSC5a/TUSC5b stable transgenic cell line.
9. The use according to claim 4, characterized in that: the method also comprises the step of packaging the bovine TUSC5a/TUSC5b gene recombinant lentivirus by over-expressing the bovine TUSC5a/TUSC5b gene recombinant lentivirus and a Pspax2 and PMD2.G three-plasmid lentivirus packaging system, and the 293T cells are used as packaging cells for packaging the lentivirus.
10. The use according to claim 9, characterized in that: pspax2: pmd2.G: the volume ratio of the recombinant lentivirus of the over-expressed bovine TUSC5a/TUSC5b gene is 2:3: 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210587879.9A CN114891832B (en) | 2022-05-27 | 2022-05-27 | Construction method and application of recombinant lentivirus for over-expressing bovine TUSC5a and TUSC5b genes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210587879.9A CN114891832B (en) | 2022-05-27 | 2022-05-27 | Construction method and application of recombinant lentivirus for over-expressing bovine TUSC5a and TUSC5b genes |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114891832A CN114891832A (en) | 2022-08-12 |
CN114891832B true CN114891832B (en) | 2023-10-27 |
Family
ID=82726814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210587879.9A Active CN114891832B (en) | 2022-05-27 | 2022-05-27 | Construction method and application of recombinant lentivirus for over-expressing bovine TUSC5a and TUSC5b genes |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114891832B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007097547A (en) * | 2005-10-07 | 2007-04-19 | Chiba Univ | Method for screening obesity-treating agent or obesity-preventing agent |
-
2022
- 2022-05-27 CN CN202210587879.9A patent/CN114891832B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007097547A (en) * | 2005-10-07 | 2007-04-19 | Chiba Univ | Method for screening obesity-treating agent or obesity-preventing agent |
Non-Patent Citations (3)
Title |
---|
KP347628.1.GenBank.2016,序列. * |
NM_001083707.1.GENEBANK.2020,序列. * |
秦川牛脂肪沉积相关基因筛选及可变剪接对基因表达 和细胞定位的影响研究;周扬;中国博士学位论文全文数据库;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN114891832A (en) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106636090A (en) | SiRNA of humanized interleukin 6, recombination expression carrier CAR-T and construction method and application of recombination expression carrier CAR-T | |
CN101979547B (en) | Identification of isolation cloning and core region of promoters suitable for gene expression of skeletal muscles in pigs | |
CN114891832B (en) | Construction method and application of recombinant lentivirus for over-expressing bovine TUSC5a and TUSC5b genes | |
CN103173481A (en) | Plasmid vector containing 3'UTR (untranslated regions) sequence of ABCB1 gene and reporter gene as well as construction method and use of plasmid vector | |
CN108531544A (en) | A kind of method of miR-181b target genes screening | |
CN116218846B (en) | Identification and application of enhancer sequence for regulating and controlling expression of Ptrf gene of pig | |
CN103173480B (en) | Method for screening multidrug resistance related microRNA (ribonucleic acid) by using dual-luciferase report genes | |
CN102604947B (en) | Porcine adipose tissue-specific chimeric promoters | |
Raina et al. | The Azotobacter vinelandii nifL-like gene: nucleotide sequence analysis and regulation of expression | |
CN111471715A (en) | Adenovirus vector and construction method and application thereof | |
CN110499316B (en) | Milk cow mammary gland epithelial cell line with CD44 gene knocked out and construction method thereof | |
CN113736742A (en) | Application of PRTN3 gene as target point for activating cytotoxic immune cells in tumor immunotherapy | |
CN109207488B (en) | Construction method and application of PE38KDEL gene expression plasmid mediated by tumor specific promoter | |
CN108118056B (en) | shRNA for inhibiting expression of bovine MSTN gene, construction vector and application thereof | |
CN108118055B (en) | shRNA for inhibiting bovine FABP4 gene expression, construction vector and application thereof | |
CN101245345B (en) | Goat S6K1 gene cDNA encoding zone nucleotide sequence | |
CN110964727A (en) | shRNA lentiviral expression vector construction method for specifically inhibiting c-myc gene expression and application thereof | |
CN112210556A (en) | Group of shRNA for targeted interference of IL-33 expression, recombinant adenovirus vector, and construction method and application thereof | |
CN112391385A (en) | siRNA, siRNA plasmid and lentivirus for targeted inhibition of NCEH1 gene expression as well as construction method and application thereof | |
CN117487009B (en) | Anti-chicken PML monoclonal antibody and application thereof | |
CN111206034B (en) | New application of pig GADD45a gene and construction and application of high-expression cell line | |
CN101979520A (en) | Core-binding factor alpha1 gene recombinant virus for specifically promoting cartilage differentiation, preparation method and application thereof | |
AU2023203035B2 (en) | Sheep pdgfd, nucleic acids encoding pdgfd and recombinant lentivirus, host cell and use thereof | |
CN111228292B (en) | Application of human TPT1/TCTP gene in preparation of antitumor drugs | |
CN105754949B (en) | Method for promoting osteogenic differentiation and inhibiting adipogenic differentiation of adipose-derived stem cells by adopting Sema3A gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |